Abstract:Introduction: Combined thyroid fine-needle aspiration (FNA) cytology and valine-to-glutamate substitution at codon 600 of B-Raf proto-oncogene, serine/threonine kinase (BRAF V600E) mutation detection are procedures used for diagnosing thyroid nodules in many Chinese tertiary institutions. This retrospective study at our institution aimed to explore the effectiveness and challenges of the combined approach in diagnosing thyroid nodules and the correlation between BRAF V600E mutation status and behavior of papillary thyroid carcinoma. Methods: Thyroid FNA cytology and BRAF V600E mutation detection results were reviewed between November 2020 and July 2022. A total of 623 patients, each of whom underwent thyroidectomy and final pathological examination after FNA cytology diagnosis, were included in the study. The relationship between the BRAF V600E mutational status and pathological parameters was analyzed using the χ2 test. The effectiveness and challenges of FNA cytology alone and the combined procedure were also evaluated based on the final pathology. Results: Of 623 patients, 591 were diagnosed with papillary thyroid carcinoma (PTC), of which 456 were positive for the BRAF V600E mutation. It demonstrated near-perfect specificity for identifying PTC, and its incidence rate showed an age-specific curve with an inverted U-shaped distribution. The final pathological examination showed that the combined procedure had a higher sensitivity (83.91%) than FNA cytology alone (63.45%) for distinguishing PTC from other lesions (p < 0.001). Mutational status was associated with a larger maximum tumor diameter (p = 0.003) and a tendency of capsular invasion (p = 0.0542) but possibly unrelated to central lymph node metastasis (p = 0.1846). Nodular goiters accounted for most benign entities initially designated as Bethesda categories III-V. Conclusion: BRAF V600E mutational analysis complements cytopathology and improves the PTC detection rate in FNA cytology samples due to the high prevalence of the mutation in China. BRAF V600E mutation does not show a statistical correlation with tumor aggressiveness. Morphological pitfalls such as histocyte aggregation, cystic-lining cells in nodular goiters, and oncocytes in Hashimoto's thyroiditis, were overwhelmingly found in BRAF V600E-negative specimens.

[New Progress of BRAF Gene and Thyroid Cancer].

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

The Role of BRAF in the Pathogenesis of Thyroid Carcinoma.

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

Research progress of BRAF V600E gene mutation in pathologic features of thyroid carcinoma and its targeted therapy

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

Clinical Significance of BRAF Mutation and Expression in Papillary Thyroid Carcinoma

Advances in targeted therapy and biomarker research in thyroid cancer

The clinical progress on association between BRAF V600E mutation and thyroid papillary carcinoma

[Clinical Role of BRAF V600E Mutation Testing in Thyroid Nodules].

Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)

Detection of BRAF Mutation and Its Clinical Significance in Thyroid Cancer

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.

Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China

Analysis of BRAF V600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies

Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies

BRAF V600E mutation and expression of its protein in papillary thyroid carcinoma

Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report

The BRAFT1799A Mutation Confers Sensitivity of Thyroid Cancer Cells to the BRAFV600E Inhibitor PLX4032 (RG7204)

Advances in Clinical Utility of BRAFV600E Mutation in Thyroid Cancer

Targeting of the BRAF gene in papillary thyroid carcinoma (Review)